Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Cross-trial efficacy comparison is roughly a tie: CagriSema ~22.7% (REDEFINE-1) vs tirzepatide ~22.5% at 15 mg (SURMOUNT-1)
- The mechanisms are fundamentally different: GLP-1 plus amylin (CagriSema) vs GLP-1 plus GIP in a single molecule (tirzepatide)
- Tirzepatide is FDA-approved for obesity (Zepbound, Nov 2023) and type 2 diabetes (Mounjaro, May 2022). CagriSema is investigational
- The interesting clinical question is not "which is bigger" but "which works better for which patient phenotype"
- CagriSema is not commercially available. FormBlends does not sell or supply it
Direct answer
The cross-trial weight-loss numbers for CagriSema (~22.7%) and tirzepatide (~22.5% at 15 mg) are statistically indistinguishable at the population level. The drugs differ in mechanism, in regulatory status, and in their long-term data depth. As of May 2026, tirzepatide is FDA-approved and widely available; CagriSema is under FDA review with a possible 2026-2027 launch. There is no clinical evidence that one is strictly superior to the other.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The headline numbers and why they are nearly identical
- The mechanism comparison
- Trial design differences that affect interpretation
- Side-effect profile comparison
- Cardiovascular and metabolic data
- Regulatory and access status
- The "right responder" question
- Cost and insurance outlook
- Switching between them
- The contrary view: why cross-trial comparisons mislead
- FAQ
- Sources
The headline numbers and why they are nearly identical
Both trials hit roughly the same weight-loss target. The methodological details:
| Trial | Drug | n | Duration | Mean weight change |
|---|---|---|---|---|
| REDEFINE-1 | CagriSema (sema 2.4 + cagri 2.4) | 3,417 | 68 weeks | ~ -22.7% |
| SURMOUNT-1 | Tirzepatide 15 mg | 2,539 | 72 weeks | ~ -22.5% |
| SURMOUNT-1 | Tirzepatide 10 mg | 2,539 | 72 weeks | ~ -19.5% |
| SURMOUNT-1 | Tirzepatide 5 mg | 2,539 | 72 weeks | ~ -15.0% |
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 weeks | ~ -14.9% |
CagriSema's 22.7% looks roughly equal to tirzepatide 15 mg's 22.5% at first glance. The honest interpretation has to account for several differences:
- REDEFINE-1 was 68 weeks; SURMOUNT-1 was 72 weeks. Weight loss continues to accumulate slowly into year two, so SURMOUNT-1 had a slight time advantage that may have padded its number
- The two trials had different rescue rules, lifestyle counseling intensities, and population characteristics (BMI distribution, age, sex ratio)
- The "estimand" used to define the primary analysis differed; REDEFINE-1 used the on-treatment estimand, which generally produces higher estimates than the treatment policy estimand
The honest conclusion: CagriSema and tirzepatide are both approximately 22-23% mean-weight-loss drugs at their highest tested doses. The difference is well within trial-to-trial noise.
The mechanism comparison
The drugs reach a similar weight-loss number through different receptor systems.
| Receptor | CagriSema | Tirzepatide |
|---|---|---|
| GLP-1 | Yes (semaglutide component) | Yes (one of two functions of the molecule) |
| GIP | No | Yes (the second function) |
| Amylin | Yes (cagrilintide component) | No |
| Glucagon | No | No |
Why the difference matters at the level of biology:
GLP-1. Both drugs activate GLP-1 receptors. This is the well-characterized pathway shared by Ozempic, Wegovy, Trulicity, Saxenda, and Rybelsus. Effects include enhanced insulin secretion, reduced glucagon, slowed gastric emptying, and central satiety signaling.
GIP. Tirzepatide adds GIP agonism. GIP is a separate gut-derived incretin. Tirzepatide's GIP activity is unusual; some preclinical work suggested GIP receptor agonism, antagonism, or biased signaling could all contribute to weight loss. The clinical-trial result is that tirzepatide produces more weight loss than semaglutide at comparable exposure, attributed to GIP involvement.
Amylin. CagriSema adds amylin. Amylin is co-secreted with insulin and acts on receptors in the area postrema and other brainstem regions. The behavioral effect is increased satiety and slowed gastric emptying through a parallel pathway. Cagrilintide alone produced ~10.8% weight loss in phase 2.
The implication for patient response: if a patient gets a partial response on semaglutide, the question is whether they would benefit more from adding GIP (tirzepatide) or amylin (CagriSema). The current evidence does not resolve that question.
Trial design differences that affect interpretation
Beyond the headline numbers, the trials differed in ways that complicate direct comparison:
| Trial feature | REDEFINE-1 | SURMOUNT-1 |
|---|---|---|
| Population | BMI 27+ with comorbidity or BMI 30+, no T2D | BMI 27+ with comorbidity or BMI 30+, no T2D |
| Baseline mean BMI | ~37 kg/m² | ~38 kg/m² |
| Sex distribution | ~75% female | ~67% female |
| Race/ethnicity | Predominantly white | Predominantly white |
| Comparator arms | Sema 2.4, cagri 2.4, placebo | Placebo only (active comparator absent) |
| Lifestyle intervention | Standard reduced-calorie diet + activity counseling | Standard reduced-calorie diet + activity counseling |
| Primary analysis | On-treatment estimand | Treatment policy estimand also reported |
The estimand difference is the most consequential. The on-treatment estimand reports the effect for participants who remain on therapy. The treatment policy estimand counts everyone regardless of discontinuation. Real-world clinical outcomes track the treatment policy estimand more closely. Tirzepatide's treatment policy result in SURMOUNT-1 was lower than its on-treatment result; the same is likely true for CagriSema, though Novo emphasized the on-treatment number in headline summaries.
Side-effect profile comparison
Both drugs produce dose-dependent GI events as the dominant side effect. Cross-trial rates are approximate and depend on definitions:
| Event | CagriSema (REDEFINE-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| Nausea (any) | ~50-55% | ~31% |
| Vomiting | ~25-30% | ~13% |
| Diarrhea | ~25-30% | ~23% |
| Constipation | ~20-25% | ~17% |
| Discontinuation for adverse events | ~6% | ~7% |
Note: tirzepatide nausea rates rose from baseline reports as the drug was used in broader real-world populations. CagriSema's higher trial-reported nausea may reflect both the amylin component (amylin signaling shares brainstem real estate with the nausea axis) and a more aggressive titration schedule. The clinical message: GI side effects are unavoidable with both, and dose titration matters.
Other safety considerations:
- Pancreatitis. Rare event with both classes. Real-world rates are not clearly elevated above background
- Gallbladder events. Increased with rapid weight loss in both
- Thyroid C-cell tumors. Boxed warning on the GLP-1 class based on rodent data. Carries over to both drugs
- Heart rate. Modest mean increase with both
- Suicidal ideation. No clear signal in either trial; ongoing post-market surveillance
Cardiovascular and metabolic data
Semaglutide has a robust cardiovascular data set through the SELECT trial, which showed a 20% relative reduction in MACE in patients with established cardiovascular disease and obesity (Lincoff et al., NEJM 2023). The cardiovascular benefit is part of the value case for any semaglutide-containing therapy, including CagriSema.
Tirzepatide cardiovascular data is from the SURPASS-CVOT trial, which read out and showed cardiovascular safety, with cardiovascular benefit results still under analysis as of mid-2025. Tirzepatide has substantial type 2 diabetes data from the SURPASS-1 through SURPASS-5 trials.
Practical implication: a patient with both obesity and established cardiovascular disease has stronger evidence for semaglutide-containing therapy (CagriSema or Wegovy) than for tirzepatide today. As more tirzepatide CV data accumulates, that gap may close.
Regulatory and access status
| Attribute | CagriSema | Tirzepatide |
|---|---|---|
| FDA approval status (May 2026) | Under review | Approved: Zepbound (Nov 2023), Mounjaro (May 2022) |
| Available through pharmacies | No | Yes |
| Telehealth availability | No | Yes |
| Insurance coverage path | To be established | Variable; some commercial plans cover Zepbound |
| Patient assistance | None yet | Lilly LillyDirect, manufacturer savings cards |
For a patient deciding today, tirzepatide is the option that exists. CagriSema is an option that may exist in 12 to 24 months. Treatment delay has its own costs.
The "right responder" question
Population mean is not the only metric. Both trials reported what fraction of participants achieved various weight-loss thresholds:
| Threshold | CagriSema (REDEFINE-1) | Tirzepatide 15 mg (SURMOUNT-1) |
|---|---|---|
| ≥ 5% weight loss | ~90% | ~91% |
| ≥ 10% weight loss | ~80% | ~83% |
| ≥ 15% weight loss | ~70% | ~71% |
| ≥ 20% weight loss | ~60% | ~57% |
| ≥ 25% weight loss | ~45% | ~40% |
The distribution of responses overlaps almost completely. Some patients respond better to one drug than the other; the trials do not identify reliable predictors of individual response. Clinical practice generally requires trial-and-error switching to find the best fit for an individual.
Cost and insurance outlook
Tirzepatide list price is in the $1,000-$1,400 per month range before insurance. Manufacturer savings cards reduce this substantially for eligible commercial-insured patients; cash prices through LillyDirect for self-pay run lower than retail.
CagriSema's price has not been announced. The likely range is comparable to Wegovy and Zepbound list prices. Novo will probably offer a savings card at launch.
Insurance dynamics:
- Commercial plans cover Zepbound at varying rates; many require step therapy through other agents
- Medicare Part D does not cover anti-obesity medications for the obesity indication, though semaglutide is covered for cardiovascular risk reduction in eligible patients
- Medicaid coverage varies by state
- Self-pay through telehealth has become a substantial market for both drugs
Switching between them
Patients sometimes switch from one to the other. Reasons include intolerance, suboptimal response, insurance changes, supply issues, and cost.
Practical notes if CagriSema becomes available:
- Switching from tirzepatide to CagriSema: titrate down tirzepatide, washout briefly, start CagriSema at the recommended initial dose. Expect a transient appetite increase between doses
- Switching from CagriSema to tirzepatide: similar, in reverse
- The "switch back" experience is common; some patients tolerate one better than the other, and switching back is reasonable
- Do not stack the two drugs. There is no evidence of additional benefit and clear risk of additive GI effects
The contrary view: why cross-trial comparisons mislead
The case against treating these drugs as interchangeable based on 22.7% vs 22.5%:
Argument 1: Trial populations differ. Two trials in nominally similar populations can produce different results because of subtle differences in BMI distribution, ethnic composition, or comorbid burden.
Argument 2: Estimands differ. The 22.7% headline number from REDEFINE-1 uses the on-treatment estimand. The treatment policy estimand produces a smaller number. Comparing the on-treatment from one trial to the treatment policy from another is apples to oranges.
Argument 3: Time horizons differ. SURMOUNT-1 ran 72 weeks; REDEFINE-1 ran 68 weeks. Four extra weeks of treatment matters at the margins.
Argument 4: Lifestyle intervention intensity differs. Both trials provided structured lifestyle counseling, but the specifics differed. Some weight-loss difference may reflect counseling intensity rather than drug effect.
Argument 5: Long-term durability is unknown. Tirzepatide has more accumulated patient-years than CagriSema. The likelihood that a 24-month outcome differs from a 12-month outcome is higher for the less-studied drug.
The reasonable conclusion: at the population level the two drugs are similar in magnitude. At the individual level, prediction is unreliable. Patients who don't respond well to one can reasonably try the other.
Decision framework
If you need to start treatment now and qualify for either: tirzepatide is the option that exists. There is no clinical case for waiting for CagriSema.
If you're already on tirzepatide and doing well: there is no reason to switch when CagriSema launches.
If you're on tirzepatide and the response has plateaued or you cannot tolerate the side effects: CagriSema, if approved, may be reasonable to consider. So is switching to maximum-dose semaglutide.
If you have type 2 diabetes: tirzepatide has the established diabetes indication and the longest track record. CagriSema's REDEFINE-2 data is encouraging but the diabetes label is not yet established.
If you have established cardiovascular disease and obesity: semaglutide-containing therapy (Wegovy now, CagriSema later) has the strongest CV evidence today.
Compounded medication note for this topic
For CagriSema vs Tirzepatide: Two Different Roads to a Similar Number, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
Which drug loses more weight, CagriSema or tirzepatide? Approximately the same at population level (~22.7% vs ~22.5%). Individual response varies.
Is CagriSema available now? No. It is under FDA review as of May 2026.
Can I take both CagriSema and tirzepatide? No. They should not be combined. There is no evidence of added benefit and predictable risk of compounded side effects.
Does CagriSema work better in women? No clear evidence of sex-specific differences in efficacy. Both drugs were tested in mixed-sex populations.
Will CagriSema cost less than tirzepatide? Unknown. Likely in a similar range at U.S. launch.
Which one has fewer side effects? Comparable overall, with tirzepatide showing slightly lower trial nausea rates. Individual experience varies widely.
Is tirzepatide better for diabetes than CagriSema? Tirzepatide has the approved diabetes indication and the SURPASS data. CagriSema's REDEFINE-2 diabetes results are not yet labeled.
Can I switch from Wegovy directly to tirzepatide? Yes, with appropriate dose titration. Many patients do.
Is CagriSema just semaglutide plus another shot? No. CagriSema is a single weekly injection containing both molecules. It is not two separate injections.
Which one has better cardiovascular evidence? Semaglutide (and by extension CagriSema's GLP-1 component) has the SELECT trial result. Tirzepatide CV outcomes data is accruing.
Will FormBlends carry CagriSema? FormBlends does not sell or supply CagriSema. It is investigational. Final commercial channels will depend on Novo's distribution strategy at launch.
Sources
- Garvey WT et al. CagriSema REDEFINE-1 Results. Presented at ObesityWeek 2024.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). New England Journal of Medicine. 2023.
- Lau DCW et al. Once-weekly cagrilintide for weight management (phase 2). Lancet. 2021.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo (STEP 4). JAMA. 2021.
- American Diabetes Association. Standards of Care in Diabetes - 2025. Diabetes Care. 2025.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
- FDA. Zepbound Prescribing Information. 2024.
- FDA. Mounjaro Prescribing Information. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with independent licensed clinicians. We are not a manufacturer, do not dispense investigational medications, and do not sell or supply CagriSema. Treatment decisions are determined by an independent prescriber based on individual medical assessment.
Investigational Drug Notice. CagriSema is investigational and not FDA-approved as of May 2026. Cross-trial efficacy comparisons summarized here are descriptive, not definitive. No head-to-head clinical trial comparing CagriSema to tirzepatide has been completed or published.
Results Disclaimer. The trial results referenced are population means. Individual outcomes vary based on adherence, dose, baseline characteristics, diet, exercise, and other factors. Achieving a specific weight-loss percentage is not guaranteed for any patient on any therapy.
Trademark Notice. CagriSema is a Novo Nordisk development designation. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →